L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

F. Cardoso, A. Costa, E. Senkus, M. Aapro, F. Andre et al., ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3), Ann Oncol, vol.28, p.3111, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01675165

J. Baselga, J. Cortes, S. B. Kim, S. A. Im, R. Hegg et al., Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, vol.366, pp.109-128, 2012.

C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu et al., Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med, vol.355, pp.2733-2776, 2006.

D. J. Slamon, B. Leyland-jones, S. Shak, H. Fuchs, V. Paton et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, vol.344, pp.783-92, 2001.

S. Verma, D. Miles, L. Gianni, I. E. Krop, M. Welslau et al., Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, vol.367, pp.1783-91, 2012.

J. Baselga, M. Campone, M. Piccart, H. A. Burris, H. S. Rugo et al., Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer, N Engl J Med, vol.366, pp.520-529, 2012.

M. Cristofanilli, N. C. Turner, I. Bondarenko, J. Ro, S. A. Im et al., Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol, vol.17, pp.425-464, 2016.

R. S. Finn, J. P. Crown, I. Lang, K. Boer, I. M. Bondarenko et al., The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, vol.16, pp.25-35, 2015.

G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke et al., Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N Engl J Med, vol.375, pp.1738-1786, 2016.

C. Twelves, M. Jove, A. Gombos, and A. Awada, Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer, Crit Rev Oncol Hematol, vol.100, pp.74-87, 2016.

V. C. Kok, Eribulin in the management of advanced breast cancer: implications of current research findings, Breast Cancer (Auckl), vol.9, pp.109-124, 2015.

J. Cortes, O. Shaughnessy, J. Loesch, D. Blum, J. L. Vahdat et al., Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, vol.377, pp.914-937, 2011.

P. A. Kaufman, A. Awada, C. Twelves, L. Yelle, E. A. Perez et al., Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, vol.33, pp.594-601, 2015.

X. Pivot, F. Marme, R. Koenigsberg, M. Guo, E. Berrak et al., Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Ann Oncol, vol.27, pp.1525-1556, 2016.

K. Aogi, H. Iwata, N. Masuda, H. Mukai, M. Yoshida et al., A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer, Ann Oncol, vol.23, pp.1441-1449, 2012.

K. Inoue, T. Saito, K. Okubo, K. Kimizuka, H. Yamada et al., Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had welldefined taxane resistance, Breast Cancer Res Treat, vol.157, pp.295-305, 2016.

L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith et al., Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, vol.27, pp.2954-61, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01440451

M. Dell'ova, D. Maio, E. Guiu, S. Roca, L. Dalenc et al., Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study, BMC Cancer, vol.15, p.659, 2015.

P. Aftimos, L. Polastro, L. Ameye, C. Jungels, J. Vakili et al., Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial, Eur J Cancer, vol.60, pp.117-141, 2016.

A. Jimeno, Eribulin: rediscovering tubulin as an anticancer target, Clin Cancer Res, vol.15, pp.3903-3908, 2009.

A. Mcbride and S. K. Butler, Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer, Am J Health Syst Pharm, vol.69, pp.745-55, 2012.

C. Twelves, J. Cortes, L. Vahdat, M. Olivo, Y. He et al., Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies, Breast Cancer Res Treat, vol.148, pp.553-61, 2014.

L. H. Schwartz, S. Litiere, E. De-vries, R. Ford, S. Gwyther et al., RECIST 1.1-Update and clarification: from the RECIST committee, Eur J Cancer, vol.62, pp.132-139, 2016.

R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, issue.1, pp.122-50, 2009.

E. Von-elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gotzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Prev Med, vol.45, pp.247-51, 2007.

A. Dufresne, X. Pivot, C. Tournigand, T. Facchini, T. Altweegg et al., Impact of chemotherapy beyond the first line in patients with metastatic breast cancer, Breast Cancer Res Treat, vol.107, pp.275-284, 2008.

L. Zelek, S. Barthier, M. Riofrio, K. Fizazi, O. Rixe et al., Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, Cancer, vol.92, pp.2267-72, 2001.

G. Lopes, S. Gluck, K. Avancha, and A. J. Montero, A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer, Breast Cancer Res Treat, vol.137, pp.187-93, 2013.